Montanova Capital LLC Takes Position in Avalyn Pharma Inc. $AVLN

Montanova Capital LLC acquired a new stake in shares of Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,503,109 shares of the company's stock, valued at approximately $82,402,000. Avalyn Pharma makes up approximately 1.4% of Montanova Capital LLC's portfolio, making the stock its 22nd largest position. Montanova Capital LLC owned 5.65% of Avalyn Pharma as of its most recent SEC filing.

Separately, Bank of New York Mellon Corp bought a new position in Avalyn Pharma in the 2nd quarter valued at $1,321,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Weiss Ratings assumed coverage on Avalyn Pharma in a research report on Thursday, August 13th. They issued a "sell (d+)" rating on the stock. Evercore assumed coverage on Avalyn Pharma in a research note on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 target price on the stock. Jefferies Financial Group began coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a "buy" rating and a $52.00 price target on the stock. Zacks Research upgraded Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Finally, Morgan Stanley boosted their price objective on Avalyn Pharma from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Avalyn Pharma has an average rating of "Moderate Buy" and an average price target of $60.00.

Avalyn Pharma Stock Performance

NASDAQ AVLN opened at $34.73 on Tuesday. Avalyn Pharma Inc. has a 52-week low of $24.15 and a 52-week high of $40.17. The stock's fifty day moving average is $31.85. The company has a market cap of $1.54 billion and a P/E ratio of -1.52. The company has a debt-to-equity ratio of 0.04, a current ratio of 33.12 and a quick ratio of 33.12.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.05. As a group, analysts forecast that Avalyn Pharma Inc. will post -3.81 EPS for the current fiscal year.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source